- • educational materials
- • procedures to protect confidential information
In addition to the duties described in ORS 414.361 (Committee to advise and make recommendations on drug utilization review standards and interventions), the Pharmacy and Therapeutics Committee shall do the following subject to the approval of the Director of the Oregon Health Authority:
(1) Publish an annual report, as described in ORS 414.382 (Requirements for annual report).
(2) Publish and disseminate educational information to prescribers and pharmacists regarding the committee and the drug use review programs, including information on the following:
(a) Identifying and reducing the frequency of patterns of fraud, abuse or inappropriate or medically unnecessary care among prescribers, pharmacists and recipients.
(b) Potential or actual severe or adverse reactions to drugs.
(c) Therapeutic appropriateness.
(d) Overutilization or underutilization.
(e) Appropriate use of generic products.
(f) Therapeutic duplication.
(g) Drug-disease contraindications.
(h) Drug-drug interactions.
(i) Drug allergy interactions.
(j) Clinical abuse and misuse.
(3) Adopt and implement procedures designed to ensure the confidentiality of any information that identifies individual prescribers, pharmacists or recipients and that is collected, stored, retrieved, assessed or analyzed by the committee, staff of the committee, the Oregon Health Authority or contractors to the committee or the authority. [2011 c.720 §5]
Note: See note under 414.351 (Definitions for ORS 414.351 to 414.414).
3 OregonLaws.org assembles these lists by analyzing references between Sections. Each listed item refers back to the current Section in its own text. The result reveals relationships in the code that may not have otherwise been apparent. Currency Information